Participant ≥1 year post bilateral lung transplantation at the time of screening
Participants presenting with CLAD Stage 1 or 2: FEV1 from \>50% to 80% of post-transplant baseline at screening and at randomization
Participants who have received at least 8 weeks of azithromycin (≥250 mg/day, at least 3 times a week) prior to randomization
You may not be if
FEV1 ≤50% of the post-transplant baseline value (CLAD 3 and 4)
Lung function decline that can be explained by non-CLAD causes including but not limited to acute lung allograft rejection (\>A1), antibody-mediated rejection, airway stenosis, or tracheobronchomalacia
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
